← Search & browse all drugs

medroxyprogesterone

L02AB02

Forms & Strengths

Tablet: 2.5 mg, 5 mg, 10 mg
Injectable suspension (Depo-Provera): 150 mg/mL
Injectable suspension (Depo-SubQ Provera 104): 104 mg/0.65 mL

Adult Dosing

Secondary amenorrhea: 5 to 10 mg daily for 5 to 10 days
Abnormal uterine bleeding: 5 to 10 mg daily for 5 to 10 days starting on day 16 or 21 of the cycle
Contraception: 150 mg IM every 3 months or 104 mg SubQ every 3 months
Endometrial or renal carcinoma (Palliative): 400 to 1000 mg IM weekly initially

Pediatric Dosing

Contraception (Adolescents): 150 mg IM every 3 months or 104 mg SubQ every 3 months
Endometriosis (Off-label): Safety and efficacy not established in pre-menarcheal pediatric patients

Indications

Contraception
Secondary amenorrhea
Abnormal uterine bleeding due to hormonal imbalance
Palliative treatment of recurrent or metastatic endometrial or renal carcinoma

Mechanism of Action

Synthetic progestin that inhibits secretion of pituitary gonadotropins
Prevents follicular maturation and ovulation
Thickens cervical mucus to inhibit sperm entry
Alters the endometrium to prevent implantation

Contraindications

Known hypersensitivity to medroxyprogesterone or components
Active thrombophlebitis or thromboembolic disorders
Undiagnosed vaginal bleeding
Known or suspected malignancy of the breast or genital organs
Severe hepatic impairment or disease
Known pregnancy

Adverse Reactions

Menstrual irregularities (amenorrhea, heavy/prolonged bleeding)
Weight gain
Headache
Dizziness
Decreased bone mineral density
Depression
Injection site reactions
Thromboembolic events (rare)

Drug Interactions

CYP3A4 inducers (e.g., carbamazepine, rifampin, St. John's wort) may decrease medroxyprogesterone concentrations and contraceptive efficacy
Aminoglutethimide may significantly reduce serum concentrations and efficacy
May alter glucose tolerance, potentially requiring adjustment of antidiabetic medications

Curated Content: Needs Vetting Before Put to Clinical Use